Presolicitation Notice Presolicitation Notice Page 3 of 3 Presolicitation Notice *=Required Field Presolicitation Notice Page 1 of 3 SUBJECT* Trastuzumab and Biosimilars GENERAL INFORMATION CONTRACTING OFFICE S ZIP CODE* 60141 SOLICITATION NUMBER* 36E79725R0038 RESPONSE DATE/TIME/ZONE 06-04-2025 2:30 PM CENTRAL TIME, CHICAGO, USA ARCHIVE 99 DAYS AFTER THE RESPONSE DATE SET-ASIDE PRODUCT SERVICE CODE* 6505 NAICS CODE* 325412 PLACE OF PERFORMANCE POSTAL CODE COUNTRY CONTACT INFORMATION CONTRACTING OFFICE ADDRESS Department of Veteran Affairs OPAL/ National Acquisition Center Building 37 1st Avenue, One block North of Cermak POINT OF CONTACT* Contract Specialist Anthony Di Crescenzo [email protected] 708-786-4984 ADDITIONAL INFORMATION AGENCY S URL URL DESCRIPTION AGENCY CONTACT S EMAIL ADDRESS [email protected] EMAIL DESCRIPTION Agency POC email DESCRIPTION PRE-SOLICITATION NOTICE:  The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79725R0038 for an unrestricted procurement for Trastuzumab and Biosimilars, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC).  VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs.  Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. Solicitation # 36E79725R0038 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about May 21, 2025, with a tentative closing date of June 4, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Anthony Di Crescenzo. Questions can be e-mailed to [email protected].    The estimated annual requirements are as follows:  REQUIREMENT DESCRIPTION  ITEM  DESCRIPTION  Package Size (mg per Vial) TOTAL EST. ANNUAL USAGE (VIALS) 1  TRASTUZUMAB 150MG/VIL INJ 150 10,297 2  TRASTUZUMAB 420MG/VIL INJ 420 1,426 *Proposed biosimilar products must be biological products licensed by the FDA under 42 U.S.C § 262 and must meet all biosimilar criteria described in 42 U.S.C. § 262. Additionally, Biosimilars Products must be FDA approved as a biologic medication that is compared to the innovator (the original biologic) and listed as a biosimilar to the innovator in the FDA Purple Book (https://purplebooksearch.fda.gov/).

Bid Protests Not Available